Richard Pasternak joins Cerenis board
This article was originally published in Scrip
Executive Summary
Cerenis Therapeutics, a biopharmaceutical company developing novel high-density lipoprotein therapies for the treatment of cardiovascular and metabolic diseases, has appointed Dr Richard Pasternak to its board of directors, increasing the number of board members to seven. Dr Pasternak was previously vice-president, head of cardiovascular clinical research and head of global scientific affairs and scientific leadership at Merck & Co from 2004-2010.